Zami Aberman
2011
In 2011, Zami Aberman earned a total compensation of $1.3M as Chief Executive Officer at Pluristem Therapeutics, a 134% increase compared to previous year.
Compensation breakdown
| Salary | $383,081 |
|---|---|
| Stock Awards | $900,900 |
| Other | $21,695 |
| Total | $1,305,676 |
Aberman received $900.9K in stock awards, accounting for 69% of the total pay in 2011.
Aberman also received $383.1K in salary and $21.7K in other compensation.
Rankings
In 2011, Zami Aberman's compensation ranked 4,700th out of 10,747 executives tracked by ExecPay. In other words, Aberman earned more than 56.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,700 out of 10,747 | 56th |
Division Manufacturing | 1,677 out of 3,960 | 58th |
Major group Chemicals And Allied Products | 347 out of 1,033 | 66th |
Industry group Drugs | 209 out of 781 | 73rd |
Industry Biological Products, Except Diagnostic Substances | 33 out of 157 | 79th |
Source: SEC filing on March 22, 2012.
Aberman's colleagues
We found one more compensation record of an executive who worked with Zami Aberman at Pluristem Therapeutics in 2011.
2011
Yaky Yanay
Pluristem Therapeutics
Chief Financial Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019